Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atevirdine Mesylate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | DRD3 | P35462 | 5/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | MDH1 | P40925 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atevirdine Mesylate SCHEMBL29377031 | 1.00 | HRH4 (0.57) | HRH4DRD2DRD3ADRA2AADORA3 | |
| Atevirdine Mesylate SCHEMBL29365699 | 1.00 | HRH4 (0.57) | HRH4DRD2DRD3ADRA2AADORA3 | |
| Atevirdine Mesylate SCHEMBL29636966 | 0.97 | ADRA2A (0.59) | HRH4DRD2DRD3ADRA2AADORA3 | |
| Atevirdine Mesylate SCHEMBL146999 | 0.97 | ADRA2A (0.59) | HRH4DRD2DRD3ADRA2AADORA3 | |
| SCHEMBL2818013 | 0.88 | ADRA2A (0.58) | HRH4DRD2DRD3ADRA2AADORA3 | |
| SCHEMBL18329597 | 0.84 | ADRA2A (0.51) | HRH4DRD2DRD3ADRA2AADORA3 | |
| SCHEMBL8985854 | 0.82 | ALDH1A1 (0.49) | DRD2DRD3KMT2AMEN1MAPT | |
| SCHEMBL9689915 | 0.81 | SLC6A7 (0.59) | DRD2DRD3KMT2AMEN1 | |
| SCHEMBL14700442 | 0.81 | ADRA2A (0.67) | HRH4DRD2DRD3ADRA2AADORA3 | |
| SCHEMBL10281154 | 0.81 | DRD2 (0.49) | DRD2DRD3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 958 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157152-A | Compositions and methods for improving the efficacy of a drug | 赫利昂生物股份有限公司 | 2023-05-23 | — | — | CN | claimed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| CN-115916175-A | Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses | 南方研究院 | 2023-04-04 | — | — | CN | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-114262344-A | Charged linkers and their use in conjugation reactions | 杭州多禧生物科技有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2021231872-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | HEALION BIO, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| CN-112272669-A | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof | 杭州多禧生物科技有限公司 | 2021-01-26 | — | — | CN | claimed |
| US-20210008104-A1 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-14 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1923173-A | Anti-cancer drugs slow release agent comprising anticancer antibiotics and booster thereof | JINAN KANGQUAN PHARMACEUTICAL (CN) | 2007-03-07 | — | — | CN | claimed |
| CN-1857723-A | Slow released anticancer medicine preparation with both amrubicin and its synergist | KANGQUAN MEDICINE SCI TECH CO (CN) | 2006-11-08 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6962900-B2 | Pharmaceutical being used for treating HIV infection, the composition and uses thereof | TIANJIN FUSOGEN BIOTECH CO., LTD. (CN) | 2005-11-08 | — | — | US | claimed |
| CN-1634584-A | Anti-cancer medicine composition containing antimetabolite | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | HRH4 3967/4885DRD2 4793/4885DRD3 4747/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | HRH4 3146/4885DRD2 4361/4885DRD3 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.